Zacks Industry Outlook Highlights: Quidel, OraSure Technologies, ResMed, Inogen and Masimo
Medical device major Medtronic plc (MDT) recently announced that it has received the FDA approval for its CoreValve Evolut PRO valve.
Medtronic plc (MDT) has released the first-ever clinical data from the Surgical Replacement and Transcatheter Aortic Valve Implantation (SURTAVI) Trial.
Mazor Robotics (MZOR) recently announced that its strategic partnership with Medtronic Plc. (MDT) for the commercialization and co-promotion of Mazor X platform, an innovative guidance system for spine surgery, is going strong.
Medtronic plc (MDT) recently won FDA approval for Melody Transcatheter Pulmonary Valve for implantation in patients whose surgical bioprosthetic pulmonary heart valves have failed.
Franklin Mutual Shares C Fund (TEMTX) seeks capital appreciation
Medical device major, Medtronic plc (MDT) recently received the U.S. FDA 510(k) clearance for its Reveal LINQ Insertable Cardiac Monitor (ICM) with TruRhythm Detection.
Medtronic plc (MDT) recently won the U.S. CMS coverage approval for its Micra Transcatheter Pacing System (TPS).
Medtronic plc (MDT) recently initiated the IN.PACT below-the-knee (BTK) study to evaluate the effectiveness of a drug-coated balloon for treatment of peripheral arterial disease (PAD).
Medtronic plc (MDT) recently presented a five-year data report on cardiac resynchronization therapy (CRT) devices within its Cardiac Rhythm & Heart Failure (CRHF) division.
This is a Real-time headline. These are breaking news, delivered the minute it happens, delivered ticker-tape style. Visit www.marketwatch.com or the quote page for more information about this breaking news.
The Zacks Analyst Blog Highlights: Home Depot, Medtronic, Kraft Heinz, Yahoo and Spectra Energy
On Feb 23, we issued an updated research report on medical device major, Medtronic plc (MDT).
Fitbit, Inc. (FIT) reported fourth-quarter 2016 adjusted loss of 63 cents per share, which was greater than the Zacks Consensus Estimate of a loss of 61 cents.
United Therapeutics Corporation (UTHR) reported adjusted earnings of $2.64 per share for fourth-quarter 2016, which missed the Zacks Consensus Estimate of $3.62 by 27.1%.
Medtronic plc'S (MDT) third-quarter fiscal 2017 Adjusted earnings per share (EPS) came in at $1.12, a penny ahead of the Zacks Consensus Estimate.